PT  - JOURNAL ARTICLE
AU  - Soneji, Samir
AU  - Beltrán-Sánchez, Hiram
AU  - Yang, JaeWon
AU  - Mann, Caroline
TI  - Population-Level Mortality Rates from Novel Coronavirus (COVID-19) in South Korea
AID  - 10.1101/2020.03.23.20041814
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.23.20041814
4099  - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041814.short
4100  - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041814.full
AB  - Background South Korea was among the first countries to report a case of the novel coronavirus (COVID-19) outside of China. As of 22 March, 2020, South Korea reported 8897 confirmed cases of and 104 deaths from COVID-19.Methods We collected the number of laboratory-confirmed cases and deaths in South Korea from the World Health Organization (as of 21 March, 2020) and case distribution and fatality rates by age from the Korean Center for Disease Control and Prevention (as of 22 March, 2020). We estimated population-level mortality rates by fitting a negative binomial regression model with the number of deaths as the outcome and population by age as an offset. We then calculated the age-standardized death rate (ASDR) based on the current COVID-19 figures and for alternative scenarios of increased prevalence.Findings The COVID-19 population-level mortality rate (per 100,000 person-years) increased with age: from 0.1 deaths among 30-39 year olds to 9.5 deaths among ≥80 year olds. The ASDR (per 100,000 person-years) was 0.8 deaths. The ASDR would increase to 52.0 deaths at a 1% prevalence (becoming the third leading cause of death) and 155.9 deaths at 3% prevalence (becoming the leading cause of death).Interpretation Currently, the population-level mortality burden of COVID-19 in South Korea, as measured by the ASDR, was relatively low compared to other causes of death partly due to the low prevalence of COVID-19. If the prevalence increases from another outbreak, the mortality burden could increase substantially and surpass other leading causes.Funding Grant P2C-HD041022, California Center for Population Research, University of California, Los Angeles (US NIH).Competing Interest StatementThe authors have declared no competing interest.Funding StatementGrant P2C-HD041022, California Center for Population Research, University of California, Los Angeles (US NIH).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull replication data for "Population-Level Mortality Rates from Novel Coronavirus (COVID-19) in South Korea" available on Harvard Dataverse. https://doi.org/10.7910/DVN/SIJ1OC